Relmada Therapeutics (RLMD) Expected to Announce Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.1450) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.09. On average, analysts expect Relmada Therapeutics to post ($0.62) EPS for the current fiscal year and ($0.78) EPS for the next fiscal year.

Relmada Therapeutics Stock Performance

NASDAQ:RLMD opened at $4.17 on Thursday. The company has a market cap of $444.81 million, a price-to-earnings ratio of -4.63 and a beta of 0.62. The stock’s fifty day moving average price is $3.81 and its two-hundred day moving average price is $5.32. Relmada Therapeutics has a 52-week low of $2.42 and a 52-week high of $8.00.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Relmada Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Insider Transactions at Relmada Therapeutics

In other Relmada Therapeutics news, CFO Maged Shenouda bought 120,200 shares of Relmada Therapeutics stock in a transaction dated Wednesday, September 9th. The shares were bought at an average price of $4.20 per share, with a total value of $504,840.00. Following the purchase, the chief financial officer owned 920,200 shares of the company’s stock, valued at $3,864,840. This trade represents a 15.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 14.50% of the company’s stock.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company’s research has primarily targeted conditions with significant unmet medical needs, including major depressive disorder and other neuropsychiatric diseases.

Relmada’s lead investigational product is REL-1017, also known as esmethadone or dextromethadone. The orally administered compound is designed to modulate the N-methyl-D-aspartate (NMDA) receptor and has been studied as a potential adjunctive treatment for major depressive disorder in patients who do not respond adequately to standard antidepressants.